Morning, Wednesday, 4th December 2019
This conference will assess the future of the life sciences sector in the UK and progress of delivering the Life Sciences Industrial Strategy and the Life Sciences Sector Deal 2 - looking at investment, innovation and next steps for policy.
- Progress in delivering the Life Sciences Industrial Strategy - with Professor Richard Barker, Chief Executive, Health Innovation Network and Director, Centre for the Advancement of Sustainable Medical Innovation and Board Member, Celgene.
Further sessions focus on:
- Moving forward with commitments in the Sector Deal 2 - investment and infrastructure, patient engagement and meeting the Industrial Strategy Grand Challenges;
- The impact of the Sector Deal to the UK economy and helping business to scale up;
- Developing partnerships between industry, the NHS, charities and universities;
- Ensuring the UK remains an attractive place for investment in life sciences;
- Regulation of medicines, medical devices and clinical trials post-Brexit;
- Supporting the uptake and adoption of innovations in the NHS; and
- Next steps for the life sciences sector in the UK.
Policy progress, key aims and delivery
Delegates will assess the progress of the Life Sciences Industrial Strategy and the Life Sciences Sector Deal 2 on accelerating the pace of growth and innovation in the UK, following investments by government and the industry.
They will discuss next steps for utilising the investments to implement key goals in the first and second Sector Deals - including for data and digital, research and development, improving access to new technologies and supporting businesses and local economies in the UK.
We expect discussion on the progress of meeting the Industrial Strategy Grand Challenge mission to transform the prevention, early diagnosis and treatment of chronic diseases by 2030 - as well as priorities for engaging patients and delivering the commitment to develop a cohort of healthy participants to enable research to diagnose diseases earlier.
Investment, regulation and ensuring UK competiveness post-Brexit
The agenda includes discussion on the impact of Brexit on the regulation of medicines and medical devices - including on patient access, supply and innovation in the UK and the relationship between the MHRA and the European Medicines Agency.
Attendees will also discuss the next steps for maintaining UK competiveness post-Brexit and the priorities for the workforce and skills retention and ensuring the UK remains an attractive place for research and development funding.
Innovation, adoption and collaboration
In light of the introduction of the Accelerated Access Collaborative, those attending will assess the progress of increasing the uptake and adoption of innovations in the NHS by providing incentives and identifying new products based on the needs of the population.
Planned sessions will assess barriers to growth, including ensuring regulation keeps pace with developments - as well as what additional support could be provided to industry and SMEs to scale up.
Following the publication of the NHS Long Term Plan, the role of partnerships with the NHS, industry, universities and charities will also be discussed - including how to further increase collaborations and engage with local systems, clinicians and patients.